Company

TaiMed Biologics, Inc.

Headquarters: Taipei, Taiwan

CEO: Dr. James Chang Ph.D.

TWSE: 4147 +1.40%

Market Cap

TW$23.95 Billion

TWD as of July 1, 2024

US$735.6 Million

Market Cap History

TaiMed Biologics, Inc. market capitalization over time

Evolution of TaiMed Biologics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of TaiMed Biologics, Inc.

Detailed Description

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody that is in Phase II clinical trials for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trials for treating HIV infections; TMB-370, a bispecific neutralizing antibody that is in Phase I clinical trials to treat HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was founded in 2007 and is headquartered in Taipei, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

TaiMed Biologics, Inc. has the following listings and related stock indices.


Stock: TWSE: 4147 wb_incandescent

Details

Headquarters:

No. 607, Ruiguang Road

3rd Floor Neihu District

Taipei, 11492

Taiwan

Phone: 886 2 2658 0058

Fax: 886 2 2658 6058